Search

everythinglearnresearchcommunity

for

Search:↓

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.

Combining specific nanoparticles with immune therapy significantly improves cancer treatment.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Dupilumab can help regrow hair and improve skin conditions in patients with severe atopic dermatitis and alopecia areata.

Baricitinib is effective as a treatment for severe hair loss.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

TNF-alpha inhibitors can cause various immune-related skin issues.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

Abrocitinib may effectively treat Lichen Planopilaris.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Rituximab effectively managed a difficult case of juvenile lupus with complications, reducing the need for steroids.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

Co-trimoxazole successfully treated a girl with multiple autoimmune symptoms.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.